tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksMarket MoversTipRanks 50 IndexDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
aTyr Pharma (ATYR)
NASDAQ:ATYR
US Market
ATYR
aTyr Pharma
Overview
Analyst Forecasts
AI Stock Analysis
Popular
Dividends
Earnings
Ownership
Financials
Statistics
New
Technical Analysis
Historical Prices
New
News & Insights
Chart
RESEARCH TOOLS
Top Analyst Stocks
Top Smart Score Stocks
Stock Screener
reports
Advertisement

aTyr Pharma (ATYR) Stock News & Sentiment

Compare
2,471 Followers
Optimistic Outlook for aTyr Pharma’s Efzofitimod: High-Risk, High-Reward Potential in Phase 3 Trial
Premium
Ratings
Optimistic Outlook for aTyr Pharma’s Efzofitimod: High-Risk, High-Reward Potential in Phase 3 Trial
11h ago
ATYR
High-Risk, High-Reward Opportunity in aTyr Pharma’s Efzofitimod Amid Upcoming Phase 3 Readout
Premium
Ratings
High-Risk, High-Reward Opportunity in aTyr Pharma’s Efzofitimod Amid Upcoming Phase 3 Readout
10d ago
ATYR
Optimistic Buy Rating for aTyr Pharma Driven by Promising Phase 3 Progress of Efzofitimod in Pulmonary Sarcoidosis
Premium
Ratings
Optimistic Buy Rating for aTyr Pharma Driven by Promising Phase 3 Progress of Efzofitimod in Pulmonary Sarcoidosis
10d ago
ATYR
Promising Outlook for aTyr Pharma’s Efzofitimod Drives Buy Rating Amid Strong Market Potential
Premium
Ratings
Promising Outlook for aTyr Pharma’s Efzofitimod Drives Buy Rating Amid Strong Market Potential
23d ago
ATYR
Promising Outlook for aTyr Pharma: Buy Rating on Efzofitimod’s Potential in Phase 3 Trial
Premium
Ratings
Promising Outlook for aTyr Pharma: Buy Rating on Efzofitimod’s Potential in Phase 3 Trial
1M ago
ATYR
Promising Phase 2 Results for aTyr Pharma’s Efzofitimod in SSc-ILD Boost Investor Confidence
Premium
Ratings
Promising Phase 2 Results for aTyr Pharma’s Efzofitimod in SSc-ILD Boost Investor Confidence
2M ago
ATYR
Positive Outlook on aTyr Pharma: Promising Phase 2 Results and Anticipation for Phase 3 Trials Justify Buy Rating
Premium
Ratings
Positive Outlook on aTyr Pharma: Promising Phase 2 Results and Anticipation for Phase 3 Trials Justify Buy Rating
2M ago
ATYR
More ATYR News >

ATYR News on the Web

Why aTyr Pharma, Inc.’s (ATYR) Stock Is Down 7.31%
AAII
Neutral
Why aTyr Pharma, Inc.’s (ATYR) Stock Is Up 15.78%
AAII
Neutral
Why aTyr Pharma, Inc.’s (ATYR) Stock Is Down 7.94%
AAII
Neutral
Why aTyr Pharma, Inc.’s (ATYR) Stock Is Up 21.56%
AAII
Neutral
Why aTyr Pharma, Inc.’s (ATYR) Stock Is Down 6.80%
AAII
Neutral
ATAI Impresses, CDTX Navigates With Confidence, MTSR Builds Momentum, COGT Keeps Scaling The Summit…
rttnews
Neutral
Why aTyr Pharma, Inc.’s (ATYR) Stock Is Up 9.50%
AAII
Neutral
Why aTyr Pharma, Inc.’s (ATYR) Stock Is Up 5.30%
AAII
Neutral

News Score - Last 7 Days

Neutral
ATYR
Sector Average
Media Buzz
This Week2 articles
Weekly Average2 articles
News Sentiment
This Week50%
Sector Average55%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is ATYR’s Media Buzz Sentiment?
2 articles about ATYR were published this week. In an average week, 2 articles are published.
    What is ATYR’s weekly average amount of articles?
    In an average week, 2 articles about ATYR are published.
      What is ATYR’s News Sentiment?
      50% of articles about ATYR were positive this week, compared to its sector average of 55%.
        Healthcare Stocks that are Trending in the News
        AMRXAmneal Pharmaceuticals
        ANIPANI Pharmaceuticals
        IONSIonis Pharmaceuticals
        CRMDCormedix
        OPKOpko Health
        Showing the stocks with the most bullish news sentiment over the past week

        Become an Expert with TipRanks Premium

        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis
        Subscribe NowSee Plans & Pricing